Perspectives in pediatric clinical trials: a review

Vihang S. Chawan, Sagar V. Badwane, Kalpesh V. Gawand, Abhishek M. Phatak, Sandeep S. Chaubey

Abstract

Children are different from adults in many aspects of pharmacotherapy, including capacity to absorb, distribute, metabolize and excrete drugs and have their own taste preferences. International Conference on Harmonisation (ICH) guidelines classify pediatric age groups into five groups namely preterm, term new born infants, infants and toddlers, children and adolescents. United States conducts maximum number of pediatric drug trials as compared to developing countries. Most of the prescribed drugs are either unlicensed or have an off label use. That is these have not been evaluated for their safety and efficacy in children. As children are separate population entity and not mini-adults, these clinical trials with adults cannot be simply generalized or extrapolated to pediatric population. Thus it is mandatory to conduct clinical trials involving pediatric population in order to get full benefits to the children. To study this gap between adults and children for their wellbeing, disease prevention, diagnosis and treatment, high quality clinical trials are required.

Keywords

Review, Child, Pediatrics, Clinical Trials, Informed consent, Pharmacology

Full Text:

PDF

References

Schedule Y. Amendment version 2005. Drugs and cosmetics rules, 1945. Available at http://dbtbiosafety.nic.in/act/schedule_y.pdf. Accessed on 18 March 2016.

International conference on harmonisation. Final Concept Paper E11 (R1): clinical investigation of medicinal products in the pediatric population. Dated 17 July 2014. Available at http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E11/E11_R1__Final_Concept_Paper_July_2014.pdf. Accessed 18 March 2016.

Dunne J, Murphy MD, Rodriguez WJ. The globalization of pediatric clinical trials. Pediatrics. 2012;130:1‑9

Ernest TB, Elder DP, Martini LG, Roberts M, Ford JL. Developing pediatric medicines: identifying the needs and recognizing the challenges. J Pharm Pharmacol. 2007;59:1043‑55.

Bavdekar SB. Pediatric clinical trials. Perspect Clin Res. 2013;4(1):89-99.

Ivanovska V, Rademaker CM, Dijk LV, Mantel-Teeuwisse AK. Pediatric drug formulations: a review of challenges and progress. Pediatrics. 2014;134(2):361-72. Available at http://dx.doi.org/10.1542/peds.2013-3225.

Zisowsky J, Krause A, Dingemanse J. Drug Development for pediatric populations: regulatory aspects pharmaceutics. 2010;2(4):364-88. Available at http://dx.doi.org/10.3390/pharmaceutics2040364.

Guidance for industry providing clinical evidence of effectiveness for human drug and biological products 1998. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078749.pdf. Accessed 18 March 2016.

The belmont report. Ethical principles and guidelines for the protection of human subjects of research. The national commission for the protection of human subjects of biomedical and behavioral research. Available at http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html. Accessed 18 March 2016.

Declaration of helsinki. Ethical principles for medical research involving human subjects. Available at http://www.wma.net/en/30publications/10policies/b3/. Accessed 18 March 2016.